• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr David M. Cutler Highlights the Importance of Reauthorizing the CHIP Program

Video

Every 5 years, the Children's Health Insurance Program (CHIP) has to be reauthorized. This year the program has to be reauthorized by September, and that normally would have happened by now, except the issue has flown under the radar with the other big healthcare issues dominating Congress' attention, explained David. M. Cutler, PhD, of Harvard University.

Every 5 years, the Children's Health Insurance Program (CHIP) has to be reauthorized. This year the program has to be reauthorized by September, and that normally would have happened by now, except the issue has flown under the radar with the other big healthcare issues dominating Congress' attention, explained David. M. Cutler, PhD, of Harvard University.

Transcript

There is a lot going on in health policy and US politics, is there anything you are afraid of going unnoticed that would normally get more attention?

There is a lot going on in health policy. I would say the biggest issue that’s flying under the radar now that people ought to be aware of is that CHIP authorization; the CHIP program needs to be reauthorized, and that has been going very slowly.

So the CHIP is the Children’s Health Insurance Program, which was created in the late 1990s, and every 5 years or so it’s needed to reauthorize it. Ordinarily, that would be no problem, everyone wants to cover children. This year, it expires in September. Normally, it would have been reauthorized by now, so the states can plan, because if they don’t have the money, they can’t cover people. And Congress hasn’t done it, and it’s sort of being held hostage to the general discussions about healthcare reform that are going on.

And I think that’s a real shame, both for, obviously, planning purposes for the states, but also for the individual children who may wind up not getting covered, or having a gap in coverage, or for when the states can’t plan what they want to do because Congress won’t reauthorize the program.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.